Recent breakthroughs in the treatment of chronic hepatitis Delta

Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolera...

Full description

Saved in:
Bibliographic Details
Published in:Le infezioni in medicina 2022, Vol.30 (2), p.204-210
Main Authors: Brancaccio, Giuseppina, Gaeta, Laura, Vitale, Alessandro, Gaeta, Giovanni B.
Format: Article
Language:English
Subjects:
Reviews
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c2295-e557c5533212bd5db13bb1c787fa1f2c33b831c737cb55d03ac36f8c5668d83c3
cites
container_end_page 210
container_issue 2
container_start_page 204
container_title Le infezioni in medicina
container_volume 30
creator Brancaccio, Giuseppina
Gaeta, Laura
Vitale, Alessandro
Gaeta, Giovanni B.
description Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.
doi_str_mv 10.53854/liim-3002-5
format article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9177179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_9177179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2295-e557c5533212bd5db13bb1c787fa1f2c33b831c737cb55d03ac36f8c5668d83c3</originalsourceid><addsrcrecordid>eNpVkN1KxDAQhYMo7rLunQ_QBzCaZHaa5EaU9RcWBNHrkKTpNtqfpY2Cb2_riuDcDGcOczh8hJxydo6gcHVRx9hQYExQPCBzgSCoypU-JHPOxYpq0GxGlsPwxsbJGddaHZMZYK6BoZ6Tq-fgQ5sy1wf7nqq--9hWQxbbLFUhS-MxNZPdlZkfzTb6rAo7m2KKQ3YT6mRPyFFp6yEsf_eCvN7dvqwf6Obp_nF9vaFeCI00IEqPCCC4cAUWjoNz3EslS8tL4QGcglGD9A6xYGA95KXymOeqUOBhQS73ubsP14RiKt3b2uz62Nj-y3Q2mv9OGyuz7T6N5lJyqceAs32A77th6EP598uZ-YFpJphmgjnqbyFlZ6g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Recent breakthroughs in the treatment of chronic hepatitis Delta</title><source>Open Access: PubMed Central</source><creator>Brancaccio, Giuseppina ; Gaeta, Laura ; Vitale, Alessandro ; Gaeta, Giovanni B.</creator><creatorcontrib>Brancaccio, Giuseppina ; Gaeta, Laura ; Vitale, Alessandro ; Gaeta, Giovanni B.</creatorcontrib><description>Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.</description><identifier>ISSN: 1124-9390</identifier><identifier>EISSN: 2532-8689</identifier><identifier>DOI: 10.53854/liim-3002-5</identifier><identifier>PMID: 35693059</identifier><language>eng</language><publisher>InfezMed</publisher><subject>Reviews</subject><ispartof>Le infezioni in medicina, 2022, Vol.30 (2), p.204-210</ispartof><rights>Copyright © 2016 - 2022 InfezMed 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2295-e557c5533212bd5db13bb1c787fa1f2c33b831c737cb55d03ac36f8c5668d83c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177179/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177179/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4023,27922,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Brancaccio, Giuseppina</creatorcontrib><creatorcontrib>Gaeta, Laura</creatorcontrib><creatorcontrib>Vitale, Alessandro</creatorcontrib><creatorcontrib>Gaeta, Giovanni B.</creatorcontrib><title>Recent breakthroughs in the treatment of chronic hepatitis Delta</title><title>Le infezioni in medicina</title><description>Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.</description><subject>Reviews</subject><issn>1124-9390</issn><issn>2532-8689</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpVkN1KxDAQhYMo7rLunQ_QBzCaZHaa5EaU9RcWBNHrkKTpNtqfpY2Cb2_riuDcDGcOczh8hJxydo6gcHVRx9hQYExQPCBzgSCoypU-JHPOxYpq0GxGlsPwxsbJGddaHZMZYK6BoZ6Tq-fgQ5sy1wf7nqq--9hWQxbbLFUhS-MxNZPdlZkfzTb6rAo7m2KKQ3YT6mRPyFFp6yEsf_eCvN7dvqwf6Obp_nF9vaFeCI00IEqPCCC4cAUWjoNz3EslS8tL4QGcglGD9A6xYGA95KXymOeqUOBhQS73ubsP14RiKt3b2uz62Nj-y3Q2mv9OGyuz7T6N5lJyqceAs32A77th6EP598uZ-YFpJphmgjnqbyFlZ6g</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Brancaccio, Giuseppina</creator><creator>Gaeta, Laura</creator><creator>Vitale, Alessandro</creator><creator>Gaeta, Giovanni B.</creator><general>InfezMed</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>2022</creationdate><title>Recent breakthroughs in the treatment of chronic hepatitis Delta</title><author>Brancaccio, Giuseppina ; Gaeta, Laura ; Vitale, Alessandro ; Gaeta, Giovanni B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2295-e557c5533212bd5db13bb1c787fa1f2c33b831c737cb55d03ac36f8c5668d83c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Reviews</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brancaccio, Giuseppina</creatorcontrib><creatorcontrib>Gaeta, Laura</creatorcontrib><creatorcontrib>Vitale, Alessandro</creatorcontrib><creatorcontrib>Gaeta, Giovanni B.</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Le infezioni in medicina</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brancaccio, Giuseppina</au><au>Gaeta, Laura</au><au>Vitale, Alessandro</au><au>Gaeta, Giovanni B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent breakthroughs in the treatment of chronic hepatitis Delta</atitle><jtitle>Le infezioni in medicina</jtitle><date>2022</date><risdate>2022</risdate><volume>30</volume><issue>2</issue><spage>204</spage><epage>210</epage><pages>204-210</pages><issn>1124-9390</issn><eissn>2532-8689</eissn><abstract>Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.</abstract><pub>InfezMed</pub><pmid>35693059</pmid><doi>10.53854/liim-3002-5</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1124-9390
ispartof Le infezioni in medicina, 2022, Vol.30 (2), p.204-210
issn 1124-9390
2532-8689
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9177179
source Open Access: PubMed Central
subjects Reviews
title Recent breakthroughs in the treatment of chronic hepatitis Delta
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T18%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20breakthroughs%20in%20the%20treatment%20of%20chronic%20hepatitis%20Delta&rft.jtitle=Le%20infezioni%20in%20medicina&rft.au=Brancaccio,%20Giuseppina&rft.date=2022&rft.volume=30&rft.issue=2&rft.spage=204&rft.epage=210&rft.pages=204-210&rft.issn=1124-9390&rft.eissn=2532-8689&rft_id=info:doi/10.53854/liim-3002-5&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_9177179%3C/pubmedcentral_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2295-e557c5533212bd5db13bb1c787fa1f2c33b831c737cb55d03ac36f8c5668d83c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/35693059&rfr_iscdi=true